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PURPOSE. To investigate the radiosensitivity of uveal melanoma
cell lines by a clonogenic survival assay, to improve the effi-
ciency of the radiation regimen.
METHODS. Four primary and four metastatic human uveal mel-
anoma cell lines were cultured in the presence of conditioned
medium. After single-dose irradiation (0–12 Gy), colonies were
allowed to form for 6 to 14 days. Two cutaneous melanomas
cell lines were also tested for comparison. The survival curves
were analyzed by the linear quadratic (LQ) model, and the
surviving fraction at a dose of 2 Gy (SF2), the SF at 10 Gy (SF10),
the ratio of initial irreparably damaged DNA (-coefficient) to
the capacity to repair sublethally damaged DNA (-coefficient),
and the plating efficiency were calculated.
RESULTS. The melanomas displayed a wide range of initial irrep-
arable DNA damage (-component), as well as a capacity for
repair of sublethal DNA damage (-component), which ulti-
mately resulted in a wide range of / ratios. These findings
were similar in both primary and metastatic melanomas and
were comparable with data obtained from two cutaneous mel-
anomas.
CONCLUSIONS. Cell lines obtained from primary and metastatic
human uveal melanomas displayed a wide range of radiosensi-
tivity, similar to that published for cutaneous melanomas.
Translating these data to the clinical setting indicates that a
fractionated dose of 8 to 10 Gy administered in three to four
fractions, as currently delivered in many centers, should be
sufficient to eradicate tumors of approximately 1 cm3. (Invest
Ophthalmol Vis Sci. 2002;43:2561–2565)
Uveal melanomas are the most common primary intraocularmalignancies in adults in the Western world, with an
annual incidence of six cases per million.1 Radiotherapy is
commonly used as the first choice for treatment of small- and
medium-sized melanomas and offers patients an eye- and vi-
sion-sparing alternative to enucleation. The introduction of
plaque radiotherapy has stimulated the search for an optimal
radiation dose to improve local control rates and reduce side
effects.2–5 High local control rates of more than 90% have been
achieved with this modality,6,7 but failures of up to 25% have
also been reported.8,9 Factors such as radiation dose, dose rate,
tumor size, tumor location, and dose distribution within the
tumor all influence the clinical outcome.10,11
External beam radiotherapy has also been tested, including
proton beam irradiation,12 helium ion therapy,13 and stereo-
tactic irradiation with a gamma knife14,15 or a linear accelera-
tor.16 With these modalities, again, high local control rates of
more than 90% have been achieved.13,16 Despite this range of
radiotherapy modalities and high local control rates, an average
of 16% to 20% of the patients undergo subsequent enucleation,
due to local tumor recurrence or uncontrollable neovascular
glaucoma.6 However, the majority of these enucleations (80%)
are due to radiotherapy-related complications.13 Acute and late
complications of ocular radiation have been reviewed exten-
sively by Finger.6 Treatment of the posteriorly located tumors
with plaque radiotherapy has been primarily associated with
such complications as retinopathy and optic neuropathy. In
contrast, after external beam irradiation, complications of the
adnexal and anterior ocular segments are more common.
To reduce side effects without diminishing tumor control
rates, studies are needed to optimize the effectiveness of radi-
ation treatment. However, little knowledge is available on the
intrinsic cellular radiosensitivity of uveal melanomas. A better
understanding of the radiosensitivity of these tumors would
improve the effectiveness of radiation schedules implemented
by ocular and radiation oncologists.
Much more is known about intrinsic cellular radiosensitivity
in cutaneous melanomas. Rofstad17 reviewed a large number of
in vitro and in vivo studies of malignant cutaneous melanomas
and reported a wide variation in radiosensitivity. This variation
could be explained partially by tumor size, but differences in
intrinsic radiosensitivity were also a prominent feature.
So far, only limited data have been published18–20 on the
cellular radiosensitivity of uveal melanoma cell lines treated
with external beam irradiation. In this article, we present data
on the cellular radiosensitivity of four primary and four meta-
static human uveal melanoma cell lines, as well as data for two
malignant cutaneous melanoma cell lines.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
In total, four primary uveal melanomas—OCM-1,21 Mel202, Mel270,22
and 92-123—and four metastatic uveal melanomas—OMM1,24
OMM2-2, OMM2-3, and OMM2-6—were tested together with the hu-
man cutaneous melanomas MelSK28 and Bowes (CRL-9607; American
Type Culture Collection [ATCC], Manassas, VA). Exponentially grow-
ing cultures were harvested and diluted in six-well plastic plates at the
required concentrations and incubated overnight before irradiation.
After irradiation, uveal melanoma cells were grown in RPMI 1640
medium with 10% fetal calf serum (FCS) diluted with conditioned
medium at 1:1 (vol/vol). Conditioned medium was collected from
passage of stock cultures and sterilized by filtration through a 0.22-m
pore size membrane (Millipore, Bedford, MA). Cutaneous melanoma
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cells were cultured in DMEM containing 10% FCS. Cells were grown
for 6 to 14 days to allow colonies to form. At 7 days after irradiation,
the medium was refreshed.
A wide range in plating efficiency was observed in both the primary
and the metastatic uveal melanoma cells. In the presence of condi-
tioned medium, higher plating efficiencies were obtained compared
with cells cultured in standard medium (data not shown). Increasing
increments of cell concentration did not improve the plating efficiency
in all cell lines used, which suggests that the given cell concentrations
in conjunction with conditioned medium produced an optimal result.
Irradiation and Clonogenic Assay
Two six-well plastic plates containing different cell lines were placed
next to each other and irradiated simultaneously in an 18 24-cm field
at a dose rate of 0.66 Gy/min using a 200-kV x-ray machine operating
at 20 mA. The x-ray machine contained a 1-mm Cu filter resulting in a
half value layer (HVL) of 1.6 mm Cu. Delivered doses were checked
with thermoluminescent dosimetry (TLD), which indicated a less than
3% dose variation over the irradiated field. Single doses of 0 to 12 Gy
were used, with one six-well plate per dose level containing two
consecutive levels of cell concentration. After irradiation, cells were
incubated for logarithmic growth of the colonies. After culturing, cells
were fixed with methanol-acetic acid 3:1 (vol/vol) for 10 minutes
followed by staining with hematoxylin. Colonies were counted under
the microscope at a magnification of 40. Colonies containing more
than 50 cells were regarded as positive.
Data Analysis
For each dose point, the number of positive colonies obtained from
three wells was averaged. These mean values were corrected for the
plating efficiency and used to calculate the cell survival for each dose
level (Excel; Microsoft, Redmond, WA). On the basis of these cell
survival data, cell survival curves were computer fitted to the linear
quadratic (LQ) model, by using the Slide Write Plus program (Ad-
vanced Graphics Software, Inc., Encinitas, CA). In this LQ model,25–27
the surviving fraction (SF) is related to total dose (D) according to SF
 exp(D D2). The -coefficient is regarded as an estimate of the
initial irreparable DNA damage, and the -coefficient represents the
capacity for DNA repair of sublethal damage. Both components are cell
and tissue specific.
Because fewer colonies were counted at higher doses, the relative
contribution of each dose level to the cell survival curve was estimated,
by using a weighting factor: (total number of plated cells  number of
colonies)/(total number of plated cells  number of colonies).
Data for each cell line from at least three experiments were aver-
aged for each cell concentration (Table 1). At the various cell concen-
trations, best-fitting values for - and -coefficients and for the SF at 2
Gy (SF2) and at 10 Gy (SF10) were calculated as estimates of the
intrinsic radiosensitivity of each cell line. The - and -coefficients
were used to derive the / ratio, the dose at which the contribution
of the linear and quadratic components are equal. For each cell survival
parameter, possible differences related to cell concentration were
examined with Student’s t-test for significance. If no significant differ-
ence with change in cell concentration was reached (two sided, P 
0.05), data were averaged.
RESULTS
The cell survival curves for the various uveal and cutaneous
melanomas are presented in Figure 1. The parameters associ-
ated with these survival curves are presented in Table 1. The
plating efficiency of these cell lines demonstrated a wide vari-
ation and ranged from as low as 4% (92-1) to 50% to 60%
(Mel2-2 and Bowes). For all cell lines tested, the cell survival
parameters listed in Table 1 did not show significant differ-
ences at different levels of cell concentration. Therefore, for
each parameter we combined the data obtained from experi-
ments at different cell concentrations. In all cases the plating
efficiency had no influence on the - or the -coefficients or on
the / ratios (correlation coefficient  0.3).
A wide range of -coefficients was found, with very high
and low values for OCM-1 (0.07761 Gy1) and for 92-1
(1.82498 Gy1), respectively. Estimates for the -coefficients
are reflected in the SF2, with high levels of survival indicative
of radioresistant cell lines and lower survival of the more
radiosensitive cell lines. The calculated -coefficients ranged
TABLE 1. Parameters for Uveal and Cutaneous Melanomas after X-irradiation for Cells Cultured in Conditioned Medium










(100–3,200) 38.9  2.7 0.07761 0.05405 1.5  0.2 0.69 20.67
Mel 270
(800–25,600) 12.5  3.0 0.55204 0.02137 26.2  2.9 0.30 4.72
OMM2–2
(200–6,400) 50.1  4.0 0.35727 0.04056 9.3  1.0 0.42 4.86
OMM2–3
(400–12,800) 18.8  1.9 0.32630 0.02799 12.7  1.5 0.48 23.29
OMM 2–6
(400–12,800) 30.6  5.7 0.27427 0.03296 9.2  1.2 0.51 23.84
Mel202
(200–25,600) 25.7  6.9 0.30645 0.03078 10.2  0.7 0.48 21.49
92-1
(400–12,800) 4.0  1.6 1.82498 — — 0.026 0.00012
OMM-1
(800–102,400) 13.2  1.0 0.67356 — — 0.26 11.88
Cutaneous melanoma
MelSK28
(200–6,400) 29.5  3.2 0.15871 0.02933 6.0  1.0 0.65 109
Bowes
(400–3,200) 60.3  9.7 0.18841 0.11696 1.6  0.4 0.43 0.0126
* Range of cells plated per well shown in parentheses.
† Data represent mean  SEM from cell survival curves, obtained from at least three separate experiments with various cell concentrations.
‡ Mean  SEM.
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from 0.02 Gy2 to 0.05 Gy2, except for the cutaneous
melanoma Bowes cell line (Table 1). This resulted in / ratios
of approximately 10 Gy for both primary and metastatic uveal
melanomas, except for OCM-1, for which a low / ratio of 1.5
Gy was calculated, which indicated the cells were spared by
dose fractionation. In contrast, for Mel270 a very high / ratio
of 26.2 Gy was obtained in conjunction with a low SF2, sug-
gesting a relatively radiosensitive cell line and a low SF after
dose fractionation. For the cell lines OMM-1 and 92-1, a very
low -component was obtained, but no value could be deter-
mined for the -component; hence, no / ratio was calcu-
lated (Table 1). This resulted in very low SF2 and SF10, indicat-
ing that these cell lines were very radiosensitive.
In both cutaneous melanomas, estimates of the -coefficient
were very similar but much higher than that of most of the
uveal melanoma cell lines. However, the -components of the
cutaneous and uveal cell lines differed by a factor of approxi-
mately 4, with a much lower value for Bowes (0.11696
Gy2). This resulted in low / ratios of 6.0 Gy and 1.6 Gy for
MelSK28 and Bowes, respectively.
DISCUSSION
Radiotherapy is commonly used as the primary choice of treat-
ment for small- and medium-sized human uveal melanomas,
because of high local control rates and the potential sparing of
the eye and vision. Currently, a range of radiotherapy modali-
ties is applied, but knowledge is still lacking concerning the
cellular radiosensitivity and hence the dose per fraction and
number of fractions required for a curative regimen. Limited
data have been published on the intrinsic radiosensitivity of
uveal melanoma cell lines.18–20
In this report, we present data regarding the radiosensitivity
of primary and metastatic human uveal melanoma cell lines,
treated with external beam irradiation and compare them with
data obtained in cutaneous melanoma cell lines.
Although caution must be exercised in using data obtained
from these in vitro studies in clinical practice, studies have
shown that in vitro survival curves of many tumor cell lines
seem to resemble the radiation sensitivity of these tumors in
vivo.28 Especially parameters related to the initial part of the
cell survival curve, such as the -component and SF2, corre-
lated with the clinical radioresponsiveness of human tumors.28
The cell lines displayed a wide range of / ratios in both
the primary and metastatic melanomas. In general cells with a
low / ratio are spared by dose fractionation and by low-dose-
rate brachytherapy, yielding lower control rates, and thus these
cells would be better treated with hypofractionation. How-
ever, a hypofractionation radiation regimen has to be balanced
against adverse ocular normal tissue toxicity. A low / ratio
was found in the uveal cell line OCM-1 and in the cutaneous
lines MelSK28 and Bowes, which indicated they were spared
by dose fractionation. For these cell lines, a relatively high
-component was calculated, as reflected in the high SF2 levels,
which were indicative of radioresistance. A similar high radio-
resistance was reported in other uveal melanomas, with SF2
higher than 0.95, and even a positive -component was calcu-
lated; hence, an estimate for the / ratio could not be deter-
mined.17,18
For cutaneous melanomas, a wide range of / ratios, from
0.5 to 60 Gy, have been reported.17,29 Approximately 66% of
the presented cases had / ratios less than 10 Gy,17 suggest-
ing that higher-than-conventional doses per fraction would be
required for effective treatment. Our results in cutaneous mel-
anomas are in agreement with these published data. Analysis of
clinical data for human cutaneous melanomas and for lymph
node lesions with histologically verified recurrent or metastatic
malignant melanoma, irradiated with doses per fraction rang-
ing from 1.8 to 10 Gy, showed a low / ratio of 0.57 Gy.30
This analysis supported the necessity of higher-than-conven-
tional doses per fraction of approximately 6 Gy recommended
for this type of tumor.
Cell lines displaying high / ratios have a reduced DNA
repair capacity, and thus cell survival is less influenced by dose
fractionation. In this situation hyperfractionation or low-dose
brachytherapy would be a viable option, because there is
preferential sparing of normal tissue cells over tumor cells. The
metastatic cell lines OMM2-2, OMM2-3, and OMM2-6 had sim-
ilar, relatively high, / ratios (9 Gy). All three metastatic cell
lines were derived from the primary cell line Mel270, which
FIGURE 1. Cell survival curves for various primary (OCM-1, Mel 270, Mel 202, 92-1) and metastatic (OMM2-2, OMM2-3, OMM2-6, OMM-1) uveal
melanomas and cutaneous melanomas (MelSK28, Bowes). Cells were cultured in standard medium in the presence of conditioned medium (1:1
vol/vol). If standard errors are not visible, they fall within the symbol. Data are survival ratios  SEM.
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itself had an even higher / ratio of approximately 26 Gy. The
Mel270 cell line was obtained from a recurrence after radio-
therapy and enucleation became inevitable. This indicated that
radiotherapy was inadequate, resulting in regrowth of original
tumor cells, or that preferentially radioresistant tumor cells
survived. A high / ratio in conjunction with a low SF2
suggests that the former of the two options is the most likely.
For two cell lines (92-1 and OMM-1), no / ratio could be
calculated, because the -component was infinite small, indi-
cating that repair of sublethal DNA damage was virtually ab-
sent. These two cell lines appeared very radiosensitive with
very low -components and SF2. Although repair of DNA dam-
age hardly occurred in these tumor cells, rendering dose frac-
tionation ineffective, dose fractionation has a substantial advan-
tage in reducing normal tissue toxicity.
The -coefficient in all cell lines ranged from 0.02 to
0.05 Gy2, except for the cutaneous melanoma line Bowes,
which showed a very low coefficient (0.117 Gy2). This low
-component indicated a lower level of cell survival compared
with that for OCM-1, which had a very similar low / ratio.
Thus, for the Bowes cell line, dose fractionation would be
appropriate (low / ratio), and smaller doses per fraction
would be adequate (low -component and SF2).
From these data, it can be calculated that for the more
radioresistant uveal cell lines, single doses of approximately 17
to 20 Gy are necessary to eradicate 109 cells, which is the
equivalent of a tumor of approximately 1 cm3. Based on the LQ
model it is calculated that dose fractionation amounting to
three to four fractions of 8 to 10 Gy is required for elimination
of 109 cells. Thus, the clinically applied schedule of 10 Gy in
five fractions should be adequate for tumors of this size.
Several factors, such as apoptosis, cell cycle disruptions, or
a combination of these factors, could be underlying mecha-
nisms for the wide range of radiosensitivity observed in the
uveal melanomas. Cell cycle disruption, and in particular loss
of the G2-cell cycle checkpoint due to mutations and DNA
methylation in the p16 gene, could influence radiosensitivity. A
p16 mutation was reported in uveal melanomas31 that corre-
lated with increased radiosensitivity after UV irradiation. In
recent publications on cutaneous melanomas, absence of the
tumor-suppresser gene p16, a cell cycle inhibitor gene,32 cor-
related with increased intrinsic radioresistance,33—a phenom-
enon also demonstrated in other tumor cell lines.34 Similar p16
mutations in uveal melanomas could correlate with changes in
radiosensitivity after ionizing radiation. Nauss NC, et al. (per-
sonal communication, 2002) reported mutations in and DNA
methylation of the p16 gene in several of the uveal melanoma
cell lines. Mel270 and its metastatic cell lines OMM2-2,
OMM2-3, and OMM2-6, as well as 92-1 and OMM-1, are all
methylated in the p16 gene. The cell line OCM-1 appears to
have a heterozygous mutation, whereas Mel202 contains a
homozygous mutation in the p16 locus. In the cutaneous
melanoma MelSK28, the p16 gene is not methylated35 and
does not contain mutations. Therefore, it can be concluded
that DNA methylation of the p16 gene does not correlate with
radiosensitivity in these uveal melanoma cell lines after ioniz-
ing radiation.
A higher capacity for sublethal DNA damage repair after
radiation would improve cell survival and consequently would
be reflected in increased radioresistance. The capacity for DNA
damage repair can be studied in more detail by using dose
fractionation. In two cell lines, the process of DNA damage
repair appeared to be absent; hence, a detailed dose fraction-
ation study for all the uveal human melanoma cell lines exam-
ined in this study is currently in progress.
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